RAPA-201 is under clinical development by Rapa Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RAPA-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RAPA-201 is under development for the treatment of relapsed and refractory multiple myeloma, solid tumor, gastric cancer, head and neck cancer, carcinoma of unknown primary, bladder cancer, non-small cell lung cancer, small-cell lung cancer, triple-negative breast cancer (TNBC), adenocarcinoma of the gastroesophageal junction, oral cavity (mouth) cancer, laryngeal cancer, nasopharyngeal cancer, melanoma and esophageal squamous cell carcinoma. The therapy comprises of autologous rapamycin-resistant T cells. It is administered through parenteral route.
Rapa Therapeutics overview
Rapa Therapeutics is a pharmaceutical and healthcare company. The company provides therapies for oncology disease. Rapa Therapeutics is headquartered in Rockville, Maryland, the US.
For a complete picture of RAPA-201’s drug-specific PTSR and LoA scores, buy the report here.